Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. insurer Anthem says Obamacare business improving; stock jumps

Anthem Inc. reported better-than-expected quarterly earnings as its Obamacare individual insurance business broke even and forecast a slight 2018 profit for the government plans despite uncertainty about the market’s future.

Read More »

HBA: Accelerating Gender Intelligence webinar series

The HBA is pleased to announce a new three-part webinar series, Accelerating Gender Intelligence.

Read More »

Amgen’s Kyprolis Meets Goals in Phase III Multiple Myeloma Study

A late-stage study shows that a stronger weekly dose of Amgen’s Kyprolis combined with dexamethasone had a greater progression-free survival benefit than a twice-weekly dose of the drug at the approved dosing level.

Read More »

Biogen Throws Another $200 Million at Aducanumab With Amended Deal With Neurimmune

Despite the failures of late-stage Alzheimer’s drugs developed by numerous companies, Biogen appears confident in the future of the company’s amyloid plaque targeting aducanumab. Biogen announced it had increased its profit potential on the drug by forking over an additional $150 million to Neurimmune Holding AG, the company from which Biogen licensed the drug. Biogen has an option to pay Neurimmune another $50 million to drop royalties by another 5 percent.

Read More »

Alexion Wins Expanded Approval for Soliris

The U.S. Food and Drug Administration expanded the approval for Alexion Pharmaceuticals Inc.’s blood-disorder drug and blockbuster medicine Soliris.

Read More »

Gilead Shows Off Mid-Stage NASH Data

Gilead Sciences released results from a Phase II clinical trial of GS-0976 for nonalcoholic steatohepatitis (NASH).

Read More »

AbbVie bets on Alzheimer’s immunotherapy with big biotech deal

U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s via a drug development deal worth more than $200 million with unlisted biotech company Alector.

Read More »

NeuroPace raises $74 million to market seizure-monitoring device

NeuroPace Inc. raised $74 million in equity funding as the medical device maker looks to rapidly expand commercialization of its device to treat epileptic seizures.

Read More »

FDA warns Meridian of violations for lead-testing devices

The U.S. Food and Drug Administration issued a warning letter to Meridian Bioscience Inc.’s unit for several federal law violations after inspecting its facility that makes lead-testing devices.

Read More »

GSK wins U.S. shingles vaccine approval

GlaxoSmithKline won U.S. approval for a new and improved shingles vaccine, the second of three key products the drugmaker expects approval for in 2017.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom